中腸神経内分泌腫瘍におけるPRRT後のソマトスタチン類似体の中止 (STOPNET)
中腸神経内分泌腫瘍におけるペプチド受容体放射性核種療法後のソマトスタチン類似体の中止に関するランダム化研究 (STOPNET)
Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce hormones which result in a variety of symptoms. However, approximately 75% of NETs are considered non-functional meaning that they do not result in hormone overproduction. The main treatment for both functional and non-functional NETs is somatostatin analogues (SSA, a type of inhibitory hormone). These drugs slow tumour growth and reduce hormone production. Over time, the majority of patients will experience tumour growth despite treatment with SSA therapy. When this occurs, the addition of Peptide Receptor Radionuclide Therapy (PRRT, a type of targeted radiotherapy) in combination with ongoing SSA therapy is given. However, it is not known if continuing SSA therapy after commencement of PRRT is beneficial or not.
The aim of this study is to estimate the outcomes of patients with grade 1 and 2 well differentiated mid, hind-gut or pancreatic neuroendocrine tumours who have progressed on SSA therapy and receive subsequent PRRT with or without concurrent SSA.
調査の概要
状態
条件
詳細な説明
Neuroendocrine tumours commonly originate from the gut and metastasise widely including to the liver, lymph nodes and bones. Originally called "carcinoid tumours", these cancers are most commonly treated with somatostatin analogues (SSA) first line. These analogues treat carcinoid syndrome and slow tumour growth. Despite SSA therapy, progression develops over time. Upon progression, peptide receptor radionuclide therapy (PRRT) is the next standard therapeutic option. After PRRT is initiated, it is unclear if continuing SSA injections is beneficial. There are reasons to believe it might be necessary to continue SSAs, but other reasons to believe they should cease. Given that SSA injections are expensive and associated with side effects, this study aims to clarify the utility of continuing SSA injections after progression on SSA therapy and commencement of PRRT.
STOPNET aims to explore outcomes in grade 1 and 2 mid, hind gut or pancreatic neuroendocrine tumours, that have progressed on SSA therapy, are eligible to receive PRRT and in whom the SSA is either continued or ceased after PRRT is commenced.
The two primary objectives include
-
To estimate the 20-month progression free survival rate after PRRT commencement in patients who cease and who continue SSA.
-
Feasibility as measured by:
- Recruitment rate and
- Patient acceptance of ceasing and staying off SSA over the 20 month follow up period.
The study design of STOPNET is prospective, randomised, non-comparative, open label, multicentre phase II study. Patients meeting the inclusion and exclusion criteria will be randomised, prior to commencing PRRT, to either continue or cease SSA treatment. Randomisation will occur centrally in REDCap by the AGITG STOPNET study team. Randomisation will be 2:1 (the majority being randomised to cease SSA) and will be stratified by WHO tumour grade (1 V 2), sites of metastases (visceral only verse visceral and bone) and institution.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:STOPNET Project Manager
- 電話番号:+61 1300 666 769
- メール:gct_stopnet_mailbox@gicancer.org.au
研究場所
-
-
New South Wales
-
Sydney、New South Wales、オーストラリア、2065
- 募集
- Royal North Shore Hospital
-
コンタクト:
- Dr David Chan
- 電話番号:+61 (02) 8037 4100
- メール:david.chan@sydney.edu.au
-
コンタクト:
- Cindy (Xiaofang) Han
- メール:Xiaofang.Han@health.nsw.gov.au
-
主任研究者:
- Dr David Chan
-
Wollongong、New South Wales、オーストラリア、2502
- 募集
- Wollongong Hospital
-
コンタクト:
- Dr Derrick Siu
- 電話番号:(02) 4222 5200
- メール:howai.siu@health.nsw.gov.au
-
コンタクト:
- Victoria Cosatto
- 電話番号:(02) 4222 5738
- メール:Victoria.Cosatto@health.nsw.gov.au
-
主任研究者:
- Dr Derrick Siu
-
-
Queensland
-
Brisbane、Queensland、オーストラリア、4006
- 募集
- Royal Brisbane and Womens Hospital
-
コンタクト:
- Poppy Sharman
- 電話番号:+61 (07) 3647 0865
- メール:Poppy.sharman@health.qld.gov.au
-
コンタクト:
- A/Prof Matthew Burge
- 電話番号:+61 07 3636 8111
- メール:Matthew.Burge@health.qld.gov.au
-
主任研究者:
- A/Prof Matthew Burge
-
Cairns、Queensland、オーストラリア、4870
- 募集
- Cairns Hospital
-
コンタクト:
- A/Prof Matthew Burge
- 電話番号:+61 (07) 4226 0000
- メール:Matthew.Burge@health.qld.gov.au
-
Toowoomba、Queensland、オーストラリア、4350
- 募集
- Toowoomba Hospital
-
コンタクト:
- A/Prof Matthew Burge
- 電話番号:+61 (07) 4616 6000
- メール:Matthew.Burge@health.qld.gov.au
-
-
South Australia
-
Adelaide、South Australia、オーストラリア、5000
- 募集
- The Queen Elizabeth Hospital
-
コンタクト:
- Prof Timothy Price
- 電話番号:08 8222 6410
- メール:Timothy.Price@sa.gov.au
-
コンタクト:
- Pam Cooper
- 電話番号:08 8222 6410
- メール:pamela.cooper@sa.gov.au
-
主任研究者:
- Prof Timothy Price
-
-
Victoria
-
Melbourne、Victoria、オーストラリア、3000
- 募集
- Peter MacCallum Cancer Centre
-
コンタクト:
- Dr Hui-Li Wong
- 電話番号:+61 3 8559 5000
- メール:HuiLi.Wong@petermac.org
-
主任研究者:
- Dr Hui-Li Wong
-
コンタクト:
- Naila Pachani
- 電話番号:+61 3 8559 5000
- メール:naila.pachani@petermac.org
-
-
Western Australia
-
Kalgoorlie-Boulder、Western Australia、オーストラリア、6430
- 募集
- Kalgoorlie Health Campus
-
コンタクト:
- Dr Piyush Grover
- 電話番号:+61 (08) 9080 5888
- メール:piyush.grover@health.wa.gov.au
-
Perth、Western Australia、オーストラリア、6150
- 募集
- Fiona Stanley Hospital
-
コンタクト:
- Dr Piyush Grover
- 電話番号:+61 08 6152 6530
- メール:piyush.grover@health.wa.gov.au
-
コンタクト:
- Anna Cannon
- 電話番号:+61 08 6152 6719
- メール:anna.cannon@health.wa.gov.au
-
主任研究者:
- Dr Piyush Grover
-
-
-
-
Alberta
-
Edmonton、Alberta、カナダ、T6G 1Z2
- 募集
- Cross Cancer Institute
-
コンタクト:
- Dr Stella Koumna
- 電話番号:780-432-8771
- メール:koumna@ualberta.ca
-
主任研究者:
- Dr Stella Koumna
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V5Z 4E6
- 募集
- BC Cancer Agency, Vancouver Cancer Centre
-
コンタクト:
- Dr Jon Loree
- 電話番号:604-877-6000
- メール:jloree@ctg.queensu.ca
-
コンタクト:
- Tathiana Ruiz
- メール:tathiana.ruiz@bccancer.bc.ca
-
主任研究者:
- Dr Jon Loree
-
-
Ontario
-
London、Ontario、カナダ、N6A 5W9
- 募集
- London Health Sciences Centre Research Institute (LHSCRI)
-
コンタクト:
- Dr David Laidley
- 電話番号:519-685-8500
- メール:David.Laidley@lhsc.on.ca
-
コンタクト:
- Alisha Moynahan
- 電話番号:519-685-8500
- メール:alisha.moynahan@lhsc.on.ca
-
主任研究者:
- Dr David Laidley
-
Ottawa、Ontario、カナダ、K1Y 1J8
- 募集
- Ottawa Hospital Research Institute
-
コンタクト:
- Dr Rachel Goodwin
- 電話番号:613-737-8899
- メール:rgoodwin@toh.ca
-
主任研究者:
- Dr Rachel Goodwin
-
Toronto、Ontario、カナダ、M5G 2M9
- 募集
- University Health Network Princess Margaret Cancer Centre
-
コンタクト:
- Dr Raymond Jang
- 電話番号:416-946-6508
- メール:raymond.jang@uhn.ca
-
主任研究者:
- Dr Raymond Jang
-
Toronto、Ontario、カナダ、TG 260
- 募集
- Odette Cancer Centre Sunnybrook Health Sciences Centre
-
コンタクト:
- Dr Sten Myrehaug
- 電話番号:416-480-4834
- メール:sten.myrehaug@sunnybrook.ca
-
主任研究者:
- Dr Sten Myrehaug
-
-
Saskatchewan
-
Regina、Saskatchewan、カナダ、S4T 7T1
- 募集
- Allan Blair Cancer Centre
-
コンタクト:
- Dr Mussawar Iqbal
- 電話番号:306-766-2213
- メール:mussawar.iqbal@saskcancer.ca
-
主任研究者:
- Dr Mussawar Iqbal
-
Saskatoon、Saskatchewan、カナダ、S7N 4H
- 募集
- Saskatoon Cancer Centre
-
コンタクト:
- Dr Mita Manna
- 電話番号:306-655-2640
- メール:mita.manna@saskcancer.ca
-
主任研究者:
- Dr Mita Manna
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Adults over 18 years of age with well or moderately differentiated mid or hindgut neuroendocrine tumour, or pancreatic neuroendocrine tumour; metastatic and inoperable, demonstrating progression despite SSA treatment of sufficient disease magnitude to warrant PRRT as determined by the treating clinician and/or the NET Multidisciplinary Team (MDT). See section 4.1 regarding the recording of the reason(s).
-
Must have measurable disease on triphasic CT/MRI as per RECIST 1.1.
-
Ki67 ≤20% AND mitotic count ≤20 per HPF (i.e., WHO grade 1 or 2).
• Note: Participants are eligible if only a single proliferation index has been performed due to local institutional practice, provided that the results are consistent with WHO grade 1 or 2 NET. However, if the results for both Ki67 and mitotic count are available, both results will need to be reported and are subject to eligibility assessment.
-
Non-functioning NET: SSA treatment will have been commenced for control of tumour growth and not for carcinoid or other hormone overproduction syndrome, as judged by the clinician and/or NET MDT. Non-functioning NET is judged by the treating clinical team based on patient symptomatology.
In addition, for this study, non-functioning tumour is defined as:
-
Never had escalation of the SSA treatment dose to control carcinoid or other hormone-related symptoms.
-
Never required short acting SSA treatment to control carcinoid or other hormone-related symptoms.
-
For mid and hind gut (GI cohort) patients:
- 24-hour urine 5-hydroxyindoleacetic acid (5HIAA) <3x upper limit of normal.
- No significant carcinoid induced valvular heart disease. I.e. Echocardiogram to be within 12 weeks of study randomisation, and deemed safe to proceed with PRRT by the treating team.
-
Note: routine measurement of gastrin, insulin, C-peptide levels, glucagon etc. is not required unless clinically indicated.
-
-
Patient has been receiving growth-controlling doses of SSA for at least 12 weeks prior to study enrolment, for example a minimum of 30mg Octreotide or 120mg Lanreotide monthly. However, other SSA formulations used at growth-controlling doses are also eligible.
-
Uptake on SSTR PET scan demonstrating somatostatin receptor expression that is suitable for PRRT as judged by the clinical team. FDG PET scans are to be done at the judgement of the treating team and are not required for enrolment into this study.
-
PRRT is deemed the most appropriate next treatment step (i.e., patient is inoperable, and liver directed therapies are not preferred).
-
ECOG performance status 0-2.
-
Written informed consent. Patients must be willing to either cease or continue SSA, depending on which study arm they are randomised to. Patients must be willing to comply with all other study requirements.
-
Adequate renal, hepatic and haematologic function as judged by the treating team.
-
Life expectancy of at least 12 months.
Exclusion Criteria:
- This study is for pancreatic, mid-gut and hind-gut NET only. Gastric and lung NETs are excluded.
- Any patient on an SSA dose lower than the standard growth-control dose. Patients must have been on an SSA equivalent to Octreotide 30mg or Lanreotide 120mg for at least 3 months prior to study enrolment.
- Prior chemotherapy or targeted therapy (e.g., everolimus). Patients who have received prior local therapy, including external beam radiotherapy and liver directed therapy prior to or during SSA therapy are eligible.
- Any contraindication to PRRT, as per local institutional practice.
- Pregnancy. For female patients of childbearing potential and male patients with a female partner who is of childbearing potential, contraception and counselling is required.
- Prior PRRT. Patients being considered for re-treatment with PRRT are not eligible.
- Uncontrolled central nervous system metastases. Patients must have completed any surgery or radiation at least 4 weeks prior to enrolment and must be off corticosteroids for at least 2 weeks.
- Any patient, in the opinion of the investigator, who will not comply with study assessments and follow up visits. These might include any social, psychological, or geographical concerns, including alcohol/drug abuse.
- Any poorly controlled concurrent medical illness that may prevent the patient from complying with study assessments and follow up. This is to be judged by the treating team.
- Any concurrent or prior malignancy that, in the opinion of the treating team, may interfere with study assessments and endpoints.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Continue SSA
Patients randomised to continue SSA will receive SSA injection 28 days (+/- 7 days) prior to the first PRRT cycle, and continue to receive SSA every 28 days (+/- 7 days) during and after the completion of PRRT. |
Patients randomised to continue SSA will receive SSA injection 28 days (+/- 7 days) prior to the first PRRT cycle, and continue to receive SSA every 28 days (+/- 7 days) during and after the completion of PRRT.
他の名前:
|
|
実験的:Cease SSA
Patients randomised to cease SSA will receive SSA injection ≥28 days prior to their first cycle of PRRT. Patients will not receive any further long acting SSA injections after this time. |
Patients randomised to cease SSA will receive their last SSA injection ≥28 days prior to their first cycle of PRRT and will remain off SSA for the duration of the study. If there is concern from the treating team that a patient may experience a carcinoid flare after PRRT, then short acting octreotide is allowed to be used to control any symptoms.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
20-month progression free survival rate after PRRT
時間枠:20 months
|
Estimate the 20-month progression free survival rate after PRRT in patients who cease and who continue SSA. |
20 months
|
|
Assess the barriers which would impede the feasibility of a subsequent phase 3 trial
時間枠:20 months
|
|
20 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Measure Quality of life using the European Organisation For Research And Treatment Of Cancer (EORTC) Core Quality of Life questionnaire (QLQ-C30) scales
時間枠:20 months
|
Responses to the QLQ-C30 scale from 0-100 using EORTC guidelines, with higher scores reflecting better level of functioning. |
20 months
|
|
Measure Quality of life using the EORTC QLQ-GINET21 scales
時間枠:20 months
|
Responses to the QLQ-GINET21 scale from 0-100 using EORTC guidelines, with higher scores reflecting more severe symptoms. |
20 months
|
|
Cost-effectiveness of SSA therapy cessation
時間枠:The MBS/PBS data will be obtained for the period six months prior to study entry, and until the end of 2 years follow-up post PRRT for patients who have provided consent.
|
Access to Medicare and PBS data to asses use of other healthcare providers, diagnostic tests and imaging services funded via public health care systems and use of pharmaceutical services respectively. |
The MBS/PBS data will be obtained for the period six months prior to study entry, and until the end of 2 years follow-up post PRRT for patients who have provided consent.
|
|
Psycho-oncological impacts of SSA therapy cessation: Decision Regret
時間枠:20 months
|
Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of Decision Regret Scale from 1 - 5 (1-Strongly Agree, 2-Agree, 3-Neither Agree Nor Disagree, 4-Disagree, 5-Strongly Disagree) |
20 months
|
|
Psycho-oncological impacts of SSA therapy cessation: Fear of Cancer Progression
時間枠:20 months
|
Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of the Fear of Cancer Progression Scale from 1 - 5 (1-Never, 2-Seldom, 3-Sometimes, 4-Often, 5-Very often) |
20 months
|
|
Psycho-oncological impacts of SSA therapy cessation: Decisional Conflict
時間枠:20 months
|
Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of the Decisional Conflict Scale from 0 - 4 (0-Strongly Agree, 1-Agree, 2-Neither Agree Nor Disagree, 3-Disagree, 4-Strongly Disagree) |
20 months
|
|
Time to commencement of subsequent therapy
時間枠:20 months
|
Time to commencement of subsequent therapy (e.g re-challenge with PRRT, liver directed therapies, chemotherapy, targeted therapies) |
20 months
|
|
Overall survival
時間枠:20 months
|
Estimate the 20-month overall survival rate in patients who cease and who continue SSA. |
20 months
|
|
Rates of SSA being recommenced over time
時間枠:20 months
|
Cumulative percentage of SSA recommencement over time. |
20 months
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Exploratory analyses
時間枠:20 months
|
Exploratory analyses including, but not limited to: Define and validate NET tissue and circulating biomarkers with a particular focus on miRNA. |
20 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- AG0219NET
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。